Hearing loss and tinnitus in survivors with chemotherapy-induced neuropathy

The purpose of this study was to evaluate for differences in demographic, clinical, and pain characteristics, as well as measures of sensation, balance, perceived stress, symptom burden, and quality of life (QOL) among survivors who received neurotoxic chemotherapy (CTX) and who reported only chemotherapy-induced neuropathy (CIN, n  = 217), CIN and hearing loss (CIN/HL, n = 69), or CIN, hearing loss, and tinnitus (CIN/HL/TIN, n = 85). We hypothesized that as the number of neurotoxicities increased, survivors would have worse outcomes.

Source: European Journal of Oncology Nursing - November 7, 2017 Category: Cancer & Oncology Authors: Christine Miaskowski, Steven M. Paul, Judy Mastick, Mark Schumacher, Yvette P. Conley, Betty Smoot, Gary Abrams, Kord M. Kober, Steven Cheung, Jennifer Henderson-Sabes, Margaret Chesney, Melissa Mazor, Margaret Wallhagen, Jon D. Levine Source Type: research